Scientific Opinion on the substantiation of health claims related to lutein and maintenance of normal vision (ID 1603, 1604, further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

EFSA Journal

Volumn 10, Issue 6, 2012, Pages

[No Author Info available]

Author keywords

health claims; Lutein; vision

Indexed keywords

EID: 84897542219     PISSN: None     EISSN: 18314732     Source Type: Journal    
DOI: 10.2903/j.efsa.2012.2716     Document Type: Article

References (12)

1. Bernstein PS, Delori FC, Richer S, van Kuijk FJ and Wenzel AJ, 2010. The value of measurement of macular carotenoid pigment optical densities and distributions in age-related macular degeneration and other retinal disorders. Vision Research, 50, 716–728.
2. Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Brockhurst RJ, Hayes KC, Johnson EJ, Anderson EJ, Johnson CA, Gaudio AR, Willett WC and Schaefer EJ, 2010. Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A. Archives of Ophthalmology, 128, 403–411.
3. Davies NP and Morland AB, 2004. Macular pigments: their characteristics and putative role. Progress in Retinal and Eye Research, 23, 533–559.
4. EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010. Scientific Opinion on the substantiation of health claims related to lutein and maintenance of vision (ID 1603, 1604, 1931) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal, 8(2):1492, 19 pp.
5. EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2011. Scientific Opinion on the substantiation of health claims related to lutein and protection of DNA, proteins and lipids from oxidative damage (ID 3427), protection of the skin from UV-induced (including photo oxidative) damage (ID 1605, 1779) and maintenance of normal vision (ID 1779, 2080) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(4):2030, 16 pp.
6. ® Lutein Esters, Lutein, or Zeaxanthin and Reduced Risk of Age-related Macular Degeneration or Cataract Formation (Docket No. 2004Q-0180).
7. Kvansakul J, Rodriguez-Carmona M, Edgar DF, Barker FM, Kopcke W, Schalch W and Barbur JL, 2006. Supplementation with the carotenoids lutein or zeaxanthin improves human visual performance. Ophthalmic and Physiological Optics, 26, 362–371.
8. Ma L, Lin XM, Zou ZY, Xu XR, Li Y and Xu R, 2009. A 12–week lutein supplementation improves visual function in Chinese people with long-term computer display light exposure. British Journal of Nutrition, 102, 186–190.
9. Rodriguez-Carmona M, Kvansakul J, Harlow JA, Kopcke W, Schalch W and Barbur JL, 2006. The effects of supplementation with lutein and/or zeaxanthin on human macular pigment density and colour vision. Ophthalmic and Physiological Optics, 26, 137–147.
10. Rodriguez-Rodriguez E, Ortega RM, Lopez-Sobaler AM, Aparicio A, Bermejo LM and Marin-Arias LI, 2006. The relationship between antioxidant nutrient intake and cataracts in older people. International Journal for Vitamin and Nutrition Research, 76, 359–366.
11. Sasaki M, Yuki K, Kurihara T, Miyake S, Noda K, Kobayashi S, Ishida S, Tsubota K and Ozawa Y, 2011. Biological role of lutein in the light-induced retinal degeneration. Journal of Nutritional Biochemistry, 23, 423–429.
12. Schalch W, Cohn W, Barker FM, Kopcke W, Mellerio J, Bird AC, Robson AG, Fitzke FF and van Kuijk FJ, 2007. Xanthophyll accumulation in the human retina during supplementation with lutein or zeaxanthin - the LUXEA (LUtein Xanthophyll Eye Accumulation) study. Archives of Biochemistry and Biophysics, 458, 128–135.